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Purpose or Objective: To investigate the association 
between external beam radiotherapy (EBRT) and pleural and 
peritoneal mesothelioma among long-term (>5 years) solid 
cancer survivors. 
 
Material and Methods: We analysed data from the US 
Surveillance, Epidemiology, and End Results (SEER) program 
(1973-2012). We fitted survival models adjusted by age, 
gender, race, year, surgery, and relative risk of primary 
mesothelioma in the county of residence (proxy for individual 
asbestos exposure). We estimated hazard ratios [HR] with 
reference to non-irradiated patients. We distinguished 
between scattered and direct irradiation to study the dose-
response. 
 
Results: We observed 300 mesotheliomas (264 pleural; 32 
peritoneal; 4 others) among 913,873 patients. EBRT increased 
the risk of mesothelioma (any site; HR 1.36, 95%CI 1.05–
1.76). We observed an increased risk of pleural mesothelioma 
(HR for EBRT 1.35, 95%CI 1.02–1.78), but we did not find signs 
of a dose-response relationship (HR for scattered irradiation 
1.35; HR for direct irradiation 1.36). On the opposite, only 
direct peritoneal irradiation was associated with peritoneal 
mesothelioma (HR 2.13, 95%CI 0.96–4.74), particularly for 
latencies ≥10 years (HR 3.19, 95%CI 1.11–9.18). A competing 
risks analysis revealed that the clinical impact of radiation-
induced mesothelioma was limited by the high frequency of 
competing events. The cumulative incidence function of 
mesothelioma after 40 years of observation was very low 
(non-irradiated patients: 0.00031, irradiated patients: 
0.00056). 
 
Conclusion: EBRT is a determinant of mesothelioma. Longer 
latency periods are associated with higher risks, while the 
dose-response seems non-linear. The clinical impact of 
mesothelioma after EBRT for primary solid cancers is very 
limited.  
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Purpose or Objective: To evaluate the clinical efficacy and 
toxicity of stereotactic body radiotherapy (SBRT) with 
respiratory motion management in patients with 
oligometastatic cancer. 
 
Material and Methods: Patients with five or less metastases 
were eligible for this prospective trial. A four-dimensional 
respiration-correlated CT (4D-CT) was obtained for planning. 
In metastases with significant motion, a fiducial marker was 
implanted for dynamic tracking using the gimbaled Vero SBRT 
system, otherwise an internal target volume (ITV) was 
defined to encompass the tumor trajectory. ITV-targets were 
also treated on Vero, unless numbering 4 or more, in which 
case tomotherapy was used. A dose of 50 Gy in 10 fractions 
of 5 Gy was prescribed on the 80% isodose line, covering the 
planning target volume.  
 
Results: We treated 87 metastases in 44 patients, with 
colorectal cancer as the most common primary origin 
(65.9%). Metastatic sites were mainly lung (n=62) and liver 
(n=17). Twenty-seven metastases, of which 12 in lung, 14 in 
liver and 1 in a kidney, were treated with dynamic tracking, 
the remaining 60 using the ITV-concept. Three patients (7%) 
experienced grade ≥3 toxicity, of which one with a liver 
metastasis invading the major bile ducts with grade 5 
cholangitis due to bile duct stenosis. After a median follow-
up of 12 months. we report an actuarial one-year local 
control (LC) of 89% for the whole group (95% CI 77–95%), with 
corresponding values of 90% and 88% for the metastases 
irradiated with the ITV-approach and dynamic tracking, 
respectively. Median progression-free survival reached 6.5 
months, one-year overall survival 97%. 
 
Conclusion: This first clinical trial on Vero dynamic tracking 
shows favorable efficacy. SBRT with respiratory motion 
management resulted in a high LC and acceptable toxicity 
profile in oligometastatic cancer patients.  
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Purpose or Objective: Contrast enhanced radiotherapy 
(CERT) has already been shown to be a promising antitumor 
modality capable to overcome some limitation inherent to 
conventional beam radiotherapy. Depth dose distribution in 
CERT is characterized by local dose increase in a volume, 
which incorporates certain amount of a high atomic number 
element. Photoabsorption of external X-ray radiation by high 
atomic number elements (such as iodine, gadolinium, gold 
etc.) leads to absorbed dose enhancement exactly in the 
region of the element location. Dose increase is caused by 
emission of short range secondary radiation such as 
characteristic X-rays, photoelectrons and Auger electrons. 
Dose enhancement in CERT for particular high atomic number 
element is strongly dependent on energy spectrum of 
external radiation. Calculations of many researchers show 
that significant part of absorbed dose is caused by Auger-
electrons especially in the close vicinity (about 1 um) of 
emitting atom. Because of their extremely short range in 
water Auger-electrons are not detectable by most dosimetric 
tools such as ionizing chambers, radiochromic films etc. 
However ferrosulfate based dosimeters (Fricke dosimeters) 
can be used to measure total absorbed dose caused by 
photoabsorption of external X-ray radiation by high atomic 
number elements. 
 
Material and Methods: Direct dose enhancement was 
measured for iodine in the chemical form of iopromide 
(Ultravist 370, Bayer) and gadolinium in the from of 
gadolinium sulfate (Sigma-Aldrich). Fricke dosimeter solution 
was prepared by standard procedure described elsewhere. 
